Navigation Links
Transgenomic Obtains Exclusive License to Mitochondrial DNA Damage Detection Technology
Date:12/4/2008

markets. The known risks, uncertainties and other factors affecting these forward-looking statements are described from time to time in Transgenomic's reports to the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. Accordingly, the company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 with respect to all statements contained in this press release. All information in this press release is as of the date of the release and Transgenomic does not undertake any duty to update this information, including any forward-looking statements, unless required by law.


'/>"/>
SOURCE Transgenomic
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine news :

1. Med-Emerg International Inc. obtains interim court order for plan of arrangement with AIM Health Group Inc.
2. China Sky One Medical, Inc. Obtains Production Approval for Two New Drugs
3. William F. McMurry - Lead Class Counsel Obtains $16.4 Million Settlement for Elderly Clients
4. China Medicine Corporation Obtains Australian Patent for rADTZ
5. DRAXIS Obtains Final Order for Proposed Arrangement
6. DRAXIS Obtains Interim Order for Proposed Arrangement
7. VIE Healthcare Expands Its Operations in the Midwest, and Obtains First Local Client
8. Aspreva obtains shareholder approval for acquisition by Galenica
9. Patient Lift Manufacturer, Medcare Products, Obtains Women-Owned Certification
10. GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc.
11. BET Networks Joins the International Call to Stop the Spread of HIV on World AIDS Day Monday, December 1 with a Special Episode of 106 & PARK Followed by BET News Exclusive ARE YOU POSITIVE?

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)...NGTON, Dec. 4 In respon... Agency,s (DEA) classification of boldione, desoxy...nedione as "anabolic steroids", under the Controll...tor and CEO of the Natural Products Association (N...resenting retailers and manufacturers of dietary s...
(Date:12/4/2009)...illion Americans are recruited annually to partici...for Human Research Protection (AHRP), and most wil...Research institutions view payments to volunteers ...ensation for potential risks related to participat...t volunteers have a very different view of clinica...
(Date:12/4/2009)... pressure from federal regulators to crack down on... Dec. 4 (HealthDay News) -- The makers of 24 diffe...federal regulators with plans to curb the abuse of...anies have been under pressure from U.S. Food and ...p the hundreds of fatal overdoses that occur with ...
(Date:12/4/2009)...sterol-lowering drugs known as statins are among t... study by researchers at Fred Hutchinson Cancer Re...tem cell transplant patients from one of the most ...erapy: graft-versus-host disease, or GVHD. The fin...the journal Blood . , In a retrospective study o...
(Date:12/4/2009)...SON, Wis., Dec. 4 When t...isconsin Department of Health Services needed to g...an ever before. Join Sonic Foundry, Inc. (Nasdaq...edia webcasting and knowledge management, for a li...Department of Health Services, will share how in-h...
Breaking Medicine News(10 mins):Health News:Natural Products Association Issues Statement on DEA's Steroid Classification Action 2Health News:Human guinea pigs wary of high-paying medical trials 2Health News:Makers of Powerful Painkillers Present Safety Plans 2Health News:Cholesterol-lowering drugs also may protect stem cell transplant patients from GVHD 2Health News:Live Webinar: Pandemic + Recession = Webcasting: Cost-Effective Streaming for Public Health Communications 2Health News:Live Webinar: Pandemic + Recession = Webcasting: Cost-Effective Streaming for Public Health Communications 3
...is less challenging for patients but equally effec... , TUESDAY, March 18 (HealthDay News) -- ...doses appears to be just as effective as conventio... the patient receives is actually less, though tre...
...O, March 18 W. Scott Harkonen,M.D., the former CE...d,felony Food, Drug and Cosmetic Act charges for h... and misleading information about the efficacy of,... indictment alleges that Harkonen, a medical docto...
...ES, N.J., March 18 BD (Becton,Dickinson and Compa...ted John,R. Considine as Vice Chairman and Chief F...f Directors, effective immediately. Mr. Considine ...e,independent with the exception of Mr. Considine ...
...lif., March 18 Transdel,Pharmaceuticals, Inc. (OT...l company focused on the development and commercia...dications, today announced that Dr.,Juliet Singh, ... Eastern Time at The Marriott Copley Place in Bost...
...ch 18 /PRNewswire-FirstCall/ - Novadaq(R) Technolo...ical imaging systems and image,guided therapies fo...and,live webcast on Tuesday, March 25, 2008 at 4:3..., dial 416-644-3417 or,1-800-732-6179. Please conn...
...group says estimate would effectively strain healt...hDay News) -- An estimated 10 million American bab...r lifetime, placing enormous strains on the U.S. h...lzheimer,s, including 200,000 to 250,000 people un...
Other Medicine News:Health News:Breast Cancer Radiation Therapy Works in Fewer, But Higher Doses 2Health News:Former InterMune CEO W. Scott Harkonen Indicted for Wire Fraud and FDA Violations 2Health News:Former InterMune CEO W. Scott Harkonen Indicted for Wire Fraud and FDA Violations 3Health News:Former InterMune CEO W. Scott Harkonen Indicted for Wire Fraud and FDA Violations 4Health News:BD Board of Directors Elects John R. Considine as Vice Chairman and Member of the Board of Directors 2Health News:Transdel Pharmaceuticals to Present at Cowen and Company's 28th Annual Health Care Conference 2Health News:Novadaq to hold fiscal 2007 year-end and fourth quarter results conference call and webcast 2Health News:Novadaq to hold fiscal 2007 year-end and fourth quarter results conference call and webcast 3Health News:10 Million Baby Boomers Face Alzheimer's, Report Predicts 2Health News:10 Million Baby Boomers Face Alzheimer's, Report Predicts 3Health News:10 Million Baby Boomers Face Alzheimer's, Report Predicts 4
(Date:12/4/2009)...Newswire-FirstCall/ -- AstraZeneca (NYSE: AZN ) ...ration (FDA) has approved once-daily SEROQUEL XR&#...s as adjunctive (add-on) treatment to antidepressa.... SEROQUEL XR is the only medication in its class ... disorder as adjunctive therapy and acute depressi...
(Date:12/3/2009)...swire-FirstCall/ -- A genetic variation that may i...ly life-threatening blood disorder if exposed to c...e of several medical discoveries scientists at can...DGX ) will present during the 51st American Societ...n, December 5-8, 2009, in New Orleans, LA. ,, ...
(Date:12/3/2009)...PRNewswire/ -- ParagonRx, a Delaware-based company...d optimal medication use, will host a free webinar... on REMS - Risk Evaluation Mitigation Strategy - p...nagement. Dr. Gary Slatko, chief medical officer ...ment programs, will lead the one-hour program begi...
Breaking Medicine Technology:US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 2US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 3US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 5US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 6US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 7US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 8US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 9Quest Diagnostics Reveals New Genetic Discoveries for Testing for Leukemia, Lymphoma and Blood Clotting at 51st ASH Meeting and Exposition 2Quest Diagnostics Reveals New Genetic Discoveries for Testing for Leukemia, Lymphoma and Blood Clotting at 51st ASH Meeting and Exposition 3Neogen Reports 18 25 Increase in Net Income 12 25 Increase in Revenues 14253 1Neogen Reports 18 25 Increase in Net Income 12 25 Increase in Revenues 14253 2Neogen Reports 18 25 Increase in Net Income 12 25 Increase in Revenues 14253 3Neogen Reports 18 25 Increase in Net Income 12 25 Increase in Revenues 14253 4Neogen Reports 18 25 Increase in Net Income 12 25 Increase in Revenues 14253 5Neogen Reports 18 25 Increase in Net Income 12 25 Increase in Revenues 14253 6Farletuzumab Data Presented on Phase II Clinical Trial in First Relapsed Ovarian Cancer Subjects 5056 1Farletuzumab Data Presented on Phase II Clinical Trial in First Relapsed Ovarian Cancer Subjects 5056 2Farletuzumab Data Presented on Phase II Clinical Trial in First Relapsed Ovarian Cancer Subjects 5056 3Farletuzumab Data Presented on Phase II Clinical Trial in First Relapsed Ovarian Cancer Subjects 5056 4HIV vaccine regimen demonstrates modest preventive effect in Thailand clinical study 58249 1HIV vaccine regimen demonstrates modest preventive effect in Thailand clinical study 58249 2HIV vaccine regimen demonstrates modest preventive effect in Thailand clinical study 58249 3
...Newswire-FirstCall/ - Alfacell Corporation,(Nasdaq...n the International,Journal of Oncology (2007; Vol...ubstantially decreases reactive oxygen intermediat.... The observed antioxidant activity,of ONCONASE ma...ells and,mechanistic synergism with other anti-can...
...ngle, Higher, More Concentrated Dose of ...f., Aug. 22 Nuvelo, Inc.,(Nasdaq: NUVO ) today a...NOMA-3 (Speedy Opening of Non-functional and Occlu...evaluating lead product candidate,alfimeprase, for...n (CO). This open-label, single-arm trial will ev...
Other Medicine Technology:Paper in International Journal of Oncology Reports Alfacell's ONCONASE(R) Suppresses Intracellular Oxidative Stress 2Paper in International Journal of Oncology Reports Alfacell's ONCONASE(R) Suppresses Intracellular Oxidative Stress 3Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion 2Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion 3Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion 4
...e laboratory and a worldwide leader in innovative ...n extensive test menu of highly complex and unique... Owned by the University of Utah, ARUP Laboratorie...university teaching hospitals and children's hospi...
...e laboratory and a worldwide leader in innovative ...n extensive test menu of highly complex and unique... Owned by the University of Utah, ARUP Laboratorie...university teaching hospitals and children's hospi...
...e laboratory and a worldwide leader in innovative ...n extensive test menu of highly complex and unique... Owned by the University of Utah, ARUP Laboratorie...university teaching hospitals and children's hospi...
...e laboratory and a worldwide leader in innovative ...n extensive test menu of highly complex and unique... Owned by the University of Utah, ARUP Laboratorie...university teaching hospitals and children's hospi...
Medicine Products: